Comparative Pharmacology
Head-to-head clinical analysis: BENADRYL versus CETIRIZINE HYDROCHLORIDE HIVES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENADRYL versus CETIRIZINE HYDROCHLORIDE HIVES.
BENADRYL vs CETIRIZINE HYDROCHLORIDE HIVES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antihistamine; inverse agonist at histamine H1 receptors, blocking histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction; also anticholinergic and sedative.
Selective inverse agonist of histamine H1 receptors, blocking histamine-mediated effects in blood vessels, respiratory smooth muscle, and gastrointestinal tract.
25-50 mg orally every 4-6 hours as needed; maximum 300 mg per day. Alternatively, 10-50 mg intramuscularly or intravenously once, maximum 100 mg per dose (IV route preferred).
10 mg orally once daily; maximum 10 mg per day.
None Documented
None Documented
Terminal elimination half-life 4-8 hours; prolonged in hepatic impairment (up to 20 hours).
Terminal elimination half-life is approximately 8–11 hours in healthy adults (mean ~8.3 h). In renal impairment (creatinine clearance <30 mL/min), half-life may be prolonged up to 20–30 hours, requiring dose adjustment.
Renal (90% as metabolites, <5% unchanged); minimal biliary/fecal.
Approximately 70% of a dose is excreted unchanged in urine via glomerular filtration and tubular secretion, with about 10% excreted in feces. Biliary elimination is minimal.
Category C
Category A/B
Antihistamine
Antihistamine